Table 2 of
Gowtham, Mol Vis 2021; 27:564-573. Table 2 of
Gowtham, Mol Vis 2021; 27:564-573.
Table 2. Demographic data of the POAG, PACG and control patients involved in this study.
| Patient demography | POAG (n=14) | PACG (n=21) | Control (n=19) |
|---|---|---|---|
| Age in years, (mean ± SD) | 53.21±11.32 | 56.42±7.88 | 58.6±5.42 |
| Median (IQR) | 52.5 (32,74) | 58 (39, 66) | 56 (36, 66) |
| Weight in Kg, (mean ± SD) | 62.79±9.84 | 59.14±9.15 | 57.35±12.78 |
| Median (IQR) | 62 (49, 83) | 60 (40, 75) | 60 (40, 74) |
| Baseline IOP in mmHg, (mean ± SD) | 33.5±10.76**** | 39.85±9.27# # # # | 14.03±3.70 |
| Median (IQR) | 30.5 (21, 56) | 40 (29, 60) | 14 (10, 18) |
| Treated IOP in mmHg, (mean ± SD) | 20.5±10.28** | 28.14±15.19# # | NA |
| Median (IQR) | 18 (14, 55) | 22 (13, 60) | NA |
| Cup-to-disc ratio (X:1), (mean ± SD) | 0.93±0.05**** | 0.86±0.12 # # # # | 0.32±0.09 |
| Median (IQR) | 0.9 (0.85, 1) | 0.9 (0.5, 1) | 0.3 (0.3, 0.5) |
| Mean arterial pressure (mmHg), (mean ± SD) | 105.05±10.64* | 101.83±20.20 | 95.46±7.73 |
| Median (IQR) | 105.17 (84, 130.67) | 101.33 (73.33, 128.35) | 97.67 (72, 104) |
| Therapeutic classes of glaucoma medications used on therapy | |||
| Prostaglandin analogs (%) | 100 | 66.67 | NA |
| Beta Blockers (%) | 85.71 | 57.14 | NA |
| Cholinergic agonist (%) | 21.43 | 76.19 | NA |
| Alpha agonist (%) | 92.86 | 66.67 | NA |
| Carbonic anhydrase inhibitors (%) | 71.43 | 71.43 | NA |